Enanta Pharma: Phase 3 GIFT-1 Study Achieves Primary Endpoint - Quick Facts

(RTTNews) - Enanta Pharmaceuticals, Inc. (ENTA) announced topline Phase 3 results from the GIFT-1 study, AbbVie's all-oral, ribavirin-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan. The company reported that the primary endpoint of the GIFT-I study was achieved, demonstrating a 95 percent sustained virologic response rate at 12 weeks post-treatment in the sub-group of previously untreated non-cirrhotic adult GT1b Japanese patients who were eligible for therapy with interferon and had a high viral load.

Paritaprevir is Enanta's lead protease inhibitor identified within the ongoing Enanta-AbbVie collaboration. AbbVie is responsible for all development and commercialization activities for paritaprevir.